BOSTON, March 30, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not...
Plexxikon Gets $15M Investment For Diabetes Drug Development (BioWorld Today)
News | 05. 27. 2004
Plexxikon
Plexxikon Inc. raised $15 million in venture financing to complete a Series B extension round.
